More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$11.00B
EPS
4
P/E ratio
32.2
Price to sales
7.53
Dividend yield
--
Beta
0.919809
Previous close
$100.27
Today's open
$101.72
Day's range
$96.40 - $101.75
52 week range
$61.23 - $134
show more
CEO
Helen I. Torley
Employees
423
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
114010000
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock?
Halozyme surges 43.1% in six months on strong ENHANZE-driven royalties and higher revenue guidance.
Zacks Investment Research • 12 hours ago

Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.
Zacks Investment Research • Nov 11, 2026

Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
Here is how Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Zacks Investment Research • Nov 10, 2026

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research • Nov 10, 2026

NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump
NVIDIA's controversy and AI market correction prompt investors to explore healthcare, consumer staples and selective semiconductor opportunities.
Zacks Investment Research • Nov 10, 2026

What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call
Halozyme Therapeutics NASDAQ: HALO raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions from newer subcutaneous drug launches.
MarketBeat • Nov 6, 2026

HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.
Zacks Investment Research • Nov 6, 2026

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.
Zacks Investment Research • Nov 6, 2026

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE®, as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication does not include patients with oropharyngeal squamous cell carcinoma that is HPV-associated.
PRNewsWire • Nov 6, 2026

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on November 5th, 2026. "Based on our analysis of CMS's final rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.
PRNewsWire • Nov 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Halozyme Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.